Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
Tempest Therapeutics (Nasdaq: TPST), a clinical-stage biotech company focused on developing first-in-class targeted and immune-mediated cancer therapeutics, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tempest Therapeutics (Nasdaq: TPST), a clinical-stage biotech company focused on developing first-in-class targeted and immune-mediated cancer therapeutics, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's senior management will engage in a fireside chat on Tuesday, December 3, 2024 at 9:00 a.m. ET. Interested parties can access both live and archived recordings of the discussion through the investor section of Tempest's website at ir.tempesttx.com.
Details
News Market Reaction – TPST
The recorded move for TPST in the trading session of this news was +2.75%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that members of senior management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 9:00 a.m. ET.
To access the live or archived recording of the discussion, please visit the investor section of the Tempest website at https://ir.tempesttx.com.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com.
Investor Contacts:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
_______________________________
i If approved by the FDA
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.